基本信息
浏览量:6
职业迁徙
个人简介
Samuel Banister is a Team Leader in Medicinal Chemistry with The Lambert Initiative for Cannabinoid Therapeutics, at the Brain and Mind Centre, The University of Sydney. His research is centred on the use of natural product scaffolds for the development of new drugs for epilepsy, neuropathic pain, depression, anxiety, substance abuse, and schizophrenia. His interest in understanding and treating diseases of the brain led him to pursue postdoctoral training in radiochemistry, positron emission tomography (PET) imaging, and translational medicine at Stanford University.
Samuel also studies the chemistry, pharmacology, and toxicology of emerging designer drugs--formally known as new psychoactive substances (NPS). He is a cofounder of the Psychoactive Surveillance Consortium and Analysis Network (PSCAN) directed by Professor Roy Gerona at UCSF, and consults to the US Drug Enforcement Administration (DEA), US Department of Homeland Security (DHS), and government laboratories in Australia and New Zealand.
Samuel is an ad hoc reviewer for multiple medicinal chemistry and molecular imaging journals, sits on the editorial advisory board of Drug Testing and Analysis, and is an enthusiastic science communicator.
BSc (Hons, First Class), The University of Sydney (2005)
PhD, The University of Sydney (2011)
Postdoctoral Research Associate, The Brain and Mind Research Institute (2012-2013)
Postdoctoral Research Fellow, Molecular Imaging Program at Stanford, Stanford Univeristy (2014-2016)
Research Scientist, Medicinal Chemistry Knowledge Center, ChEM-H, Stanford University (2017)
Samuel also studies the chemistry, pharmacology, and toxicology of emerging designer drugs--formally known as new psychoactive substances (NPS). He is a cofounder of the Psychoactive Surveillance Consortium and Analysis Network (PSCAN) directed by Professor Roy Gerona at UCSF, and consults to the US Drug Enforcement Administration (DEA), US Department of Homeland Security (DHS), and government laboratories in Australia and New Zealand.
Samuel is an ad hoc reviewer for multiple medicinal chemistry and molecular imaging journals, sits on the editorial advisory board of Drug Testing and Analysis, and is an enthusiastic science communicator.
BSc (Hons, First Class), The University of Sydney (2005)
PhD, The University of Sydney (2011)
Postdoctoral Research Associate, The Brain and Mind Research Institute (2012-2013)
Postdoctoral Research Fellow, Molecular Imaging Program at Stanford, Stanford Univeristy (2014-2016)
Research Scientist, Medicinal Chemistry Knowledge Center, ChEM-H, Stanford University (2017)
研究兴趣
论文共 120 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Biochemical pharmacology (2024): 116052-116052
Eric Sparkes,Jack Markham,Rochelle Boyd,Michael Udoh, Rebecca Gordon, Humayra Zaman, Katelyn Walker, Chianna Dane,Richard Kevin,Marina Santiago,David Hibbs,Samuel Banister,
RSC Medicinal Chemistry (2024)
Eric Sparkes, Axelle Timmerman,Jack W Markham,Rochelle Boyd, Rebecca Gordon, Katelyn A Walker,Richard C Kevin,David E Hibbs,Samuel D Banister,Elizabeth A Cairns,Christophe Stove,Adam Ametovski
PHARMACOLOGY RESEARCH & PERSPECTIVESno. 6 (2023): e01157-e01157
Theranosticsno. 12 (2022): 5335-5336
Liesl K Janssens,Adam Ametovski,Eric Sparkes,Rochelle Boyd,Felcia Lai,Callan J Maloney, Dane Rhook,Roy R Gerona, Matthew Connolly,Huiling Liu,David E Hibbs,Elizabeth A Cairns,
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn